Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Cancer Center
mi
from
Eugene, OR
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Center
mi
from
Eugene, OR
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of the Carolinas, Seneca
mi
from
Seneca, SC
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of the Carolinas, Seneca
mi
from
Seneca, SC
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center-Abilene (South)
mi
from
Abilene, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center-Abilene (South)
mi
from
Abilene, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center
mi
from
Arlington, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center At Medical City
mi
from
Dallas, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center At Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Texas Cancer Center
mi
from
Dallas, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Texas Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Center - Denton
mi
from
Denton, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Center - Denton
mi
from
Denton, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
San Antonio Tumor and Blood Clinic
mi
from
Fredericksburg, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
San Antonio Tumor and Blood Clinic
mi
from
Fredericksburg, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Houston, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Longview Cancer Center
mi
from
Longview, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Longview Cancer Center
mi
from
Longview, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
South Texas Cancer Center - McAllen
mi
from
McAllen, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
South Texas Cancer Center - McAllen
mi
from
McAllen, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Allison Cancer Center
mi
from
Midland, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
HOAST - New Braunfels
mi
from
New Braunfels, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
HOAST - New Braunfels
mi
from
New Braunfels, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
West Texas Cancer Center
mi
from
Odessa, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
West Texas Cancer Center
mi
from
Odessa, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center - Sherman
mi
from
Sherman, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Waco Cancer Care and Research Center
mi
from
Waco, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Waco Cancer Care and Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Onc and Hem Associates of SW VA, Inc.
mi
from
Salem, VA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Onc and Hem Associates of SW VA, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Puget Sound Cancer Center-Emonds
mi
from
Edmonds, WA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Puget Sound Cancer Center-Emonds
mi
from
Edmonds, WA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Puget Sound Cancer Center - Seattle
mi
from
Seattle, WA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Puget Sound Cancer Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest-South
mi
from
Spokane, WA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest-South
mi
from
Spokane, WA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists-Vancouver
mi
from
Vancouver, WA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists-Vancouver
mi
from
Vancouver, WA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
Status: Enrolling
Updated:  12/31/1969
U.T.M.D. Anderson Cancer Center
mi
from
Houston, TX
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
Status: Enrolling
Updated: 12/31/1969
U.T.M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates
mi
from
Phoenix, AZ
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Connecticut Oncology and Hematology LLP
mi
from
Torrington, CT
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Connecticut Oncology and Hematology LLP
mi
from
Torrington, CT
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Cancer Care & Hematology Specialista of Chicagoland
mi
from
Niles, IL
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Cancer Care & Hematology Specialista of Chicagoland
mi
from
Niles, IL
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Hope Center
mi
from
Terre Haute, IN
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Hope Center
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Alliance Hematology Oncology PA.
mi
from
Westminster, MD
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Alliance Hematology Oncology PA.
mi
from
Westminster, MD
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
St Joseph Oncology
mi
from
Saint Joseph, MO
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
St Joseph Oncology
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Arch Medical Services, Inc. DBA The Cntr for Cancer Care & Research
mi
from
Saint Louis, MO
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Arch Medical Services, Inc. DBA The Cntr for Cancer Care & Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
NH Oncology-Hematology, PA
mi
from
Hooksett, NH
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
NH Oncology-Hematology, PA
mi
from
Hooksett, NH
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Click here to add this to my saved trials